

Supplementary Table S1. CSF biomarker values and MRI findings in Amsterdam dementia cohort.

Characteristic	Controls (n: 16)	VaD (n: 16)	AD (n: 39)
CSF biomarkers, pg/mL			
CSF A β ₁₋₄₂	972 \pm 249	815 \pm 251	637 \pm 146 ^{a,b}
CSF t-tau	316 \pm 160	396 \pm 192	725 \pm 540 ^{a,b}
CSF p-tau	55 \pm 18	53 \pm 22	97 \pm 49 ^{a,b}
MRI characteristics, No (%)			
WML > 1	10 (60)	16 (100) ^a	30 (73.95) ^{a,b}
Lacunes present	0 (0)	13 (81) ^a	2 (5)
MTA > 1	1 (3)	14 (87) ^a	18 (45) ^{a,b}

Continuous variables are expressed as mean \pm SEM or median (interquartile range); categorical variables are expressed as percentage within group; ^a $p < 0.05$ vs CONTROLS; ^b $p < 0.05$ vs VaD. Abbreviations: CVD, cardiovascular diseases; MMSE, Mini Mental State Examination; WMLs white mass lesions; MTA, medial temporal lobe atrophy (MTA). Statistical analysis was performed using ANOVA followed by Sidak post hoc test

Supplementary Table S2. Serum Apo A1 and PON-arylesterase/Apo A1 ratio in ADC

Characteristic	CONTROLS (n: 16)	VAD (n: 16)	AD (n: 39)
Apo A1 ($\mu\text{mol/L}$)	55 \pm 9	53 \pm 10	55 \pm 8
PON-Arylesterase/Apo A1 (kU/μmol)	2.2 \pm 0.4	1.9 \pm 0.5	2.0 \pm 0.4

Continuous variables are expressed as mean \pm SEM. Statistical analysis was performed using ANOVA followed by Sidak post hoc test

Supplementary Table S3. Age and serum PON-arylesterase activity in younger (< 71 years) subjects of FC

Characteristic	CONTROLS (n: 36)	VaD (n: 14)	AD (n: 14)
Age (years)	64 ± 5	67 ± 4	67 ± 3
PON-Arylesterase (kU/L)	106 ± 23	95 ± 32	101 ± 26

Continuous variables are expressed as mean ± SEM. Statistical analysis was performed using ANOVA followed by Sidak post hoc test

Supplementary Table S4. Age and serum PON-arylesterase in older subjects (> 71 years) of FC


Characteristic	CONTROLS (n: 102)	VaD (n: 77)	LOAD (n: 260)
Age (years)	79 ± 4	80 ± 5	80 ± 5
PON-Arylesterase (kU/L)	101 ± 28	88 ± 29 ^a	87 ± 16 ^a

Continuous variables are expressed as mean ± SEM. Statistical analysis was performed using ANOVA followed by Sidak post hoc test. ^a*p* < 0.05 vs CONTROLS.

Supplementary Table S5. PON-arylesterase, APO A1 and PON-arylesterase/Apo A1 ratio in CSF of ADC

Characteristic	CONTROLS (n: 16)	VaD (n: 16)	LOAD (n: 39)
PON-Arylesterase (kU/L)	0.09 ± 0.02	0.07 ± 0.03	0.07 ± 0.04
Apo A1 (μmol/L)	0.03 ± 0.01	0.02 ± 0.00	0.03 ± 0.01
PON-Arylesterase/Apo A1 (U/μmol)	2.9 ± 1.0	2.7 ± 1.0	2.6 ± 0.8

Continuous variables are expressed as mean ± SEM. Statistical analysis was performed using ANOVA followed by Sidak post hoc test



Supplemental Figure S1 Correlation between serum and CSF PON-arylesterase (**A**), and between serum and CSF APO A1 (**B**). Pearson's correlation test was used to test the association between the variables of interest among subjects of ADC ($n = 71$).